Evidence map›Paper›PMID 25289675›Full record

ArticlePloS one2014

Deep sequencing reveals low incidence of endogenous LINE-1 retrotransposition in human induced pluripotent stem cells.

Hubert Arokium, Masakazu Kamata, Sanggu Kim, Namshin Kim, Min Liang, Angela P Presson, Irvin S Chen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Retrotransposons in embryogenesis and neurodevelopment.Biochemical Society transactions · 2024
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Hubert ArokiumDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
Masakazu KamataDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
Sanggu KimDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
Namshin KimKorean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea.
Min LiangDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
Angela P PressonDepartment of Biostatistics, University of California Los Angeles School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America.
Irvin S ChenDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
University of California, Los Angeles · USKorea Research Institute of Bioscience and Biotechnology · KR

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Defining a therapeutic threshold in HSPC gene therapy for HIV-1 diseaseR00HL116234 · NHLBI · OHIO STATE UNIVERSITY · PI KIM, SANGGU · 2016 to 2018
$747k
Defining a therapeutic threshold in HSPC gene therapy for HIV-1 diseaseK99HL116234 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIM, SANGGU · 2012 to 2013
$178k
NHLBI NIH HHS K99 HL116234NHLBI NIH HHS R00 HL116234NIAID NIH HHS 5P30 AI028697NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

Long interspersed element-1 (LINE-1 or L1) retrotransposition induces insertional mutations that can result in diseases. It was recently shown that the copy number of L1 and other retroelements is stable in induced pluripotent stem cells (iPSCs). However, by using an engineered reporter construct over-expressing L1, another study suggests that reprogramming activates L1 mobility in iPSCs. Given the potential of human iPSCs in therapeutic applications, it is important to clarify whether these cells harbor somatic insertions resulting from endogenous L1 retrotransposition. Here, we verified L1 expression during and after reprogramming as well as potential somatic insertions driven by the most active human endogenous L1 subfamily (L1Hs). Our results indicate that L1 over-expression is initiated during the reprogramming process and is subsequently sustained in isolated clones. To detect potential somatic insertions in iPSCs caused by L1Hs retotransposition, we used a novel sequencing strategy. As opposed to conventional sequencing direction, we sequenced from the 3' end of L1Hs to the genomic DNA, thus enabling the direct detection of the polyA tail signature of retrotransposition for verification of true insertions. Deep coverage sequencing thus allowed us to detect seven potential somatic insertions with low read counts from two iPSC clones. Negative PCR amplification in parental cells, presence of a polyA tail and absence from seven L1 germline insertion databases highly suggested true somatic insertions in iPSCs. Furthermore, these insertions could not be detected in iPSCs by PCR, likely due to low abundance. We conclude that L1Hs retrotransposes at low levels in iPSCs and therefore warrants careful analyses for genotoxic effects.

Indexed as

Long Interspersed Nucleotide ElementsRetroelementsCell LineCellular ReprogrammingGene Expression RegulationGenome-Wide Association StudyGerm CellsHigh-Throughput Nucleotide SequencingHumansInduced Pluripotent Stem CellsMutagenesis, InsertionalRetroelements

Identifiers

PMID25289675
PMCPMC4188539
OpenAlexW2064063353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.